Epigenomics AG Presents Positive Prognostic Biomarker Data From Studies In Prostate And Breast Cancer At American Association for Cancer Research
10/19/2005 5:13:02 PM
Epigenomics AG (Frankfurt, Prime Standard: ECX), a molecular diagnostics company developing tests based on DNA methylation, announced today that it has presented positive results from studies evaluating the prognostic value of specific biomarkers incorporated into its prostate cancer biopsy and breast cancer outcome tissue-based disease prediction tests. The data were presented as part of the 96th Annual Meeting of the American Association for Cancer Research (AACR) in Anaheim, California, USA.
comments powered by